

Jorge G. Ruiz
Olga Theou
Editors

Frailty

A Multidisciplinary Approach
to Assessment, Management, and
Prevention

Frailty

Jorge G. Ruiz • Olga Theou
Editors

Frailty

A Multidisciplinary Approach to Assessment,
Management, and Prevention

 Springer

Editors

Jorge G. Ruiz
Memorial Healthcare System
Hollywood, FL, USA

Olga Theou
Dalhousie University
Halifax, NS, Canada

ISBN 978-3-031-57360-6 ISBN 978-3-031-57361-3 (eBook)
<https://doi.org/10.1007/978-3-031-57361-3>

© The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2024
This work is subject to copyright. All rights are solely and exclusively licensed by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This Springer imprint is published by the registered company Springer Nature Switzerland AG
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

If disposing of this product, please recycle the paper.

To the pillars of my life, my mother Laura and my wife Nieves, whose unwavering support, boundless love, and enduring strength have been the guiding lights on my journey.

—Jorge G. Ruiz, MD, FACP

To my yiayia, who at the age of 100 continues to be the biggest inspiration for my work on aging and frailty.

—Olga Theou, PhD

Preface

We take pride in presenting this groundbreaking, multi-authored book, *Frailty: A Multidisciplinary Approach to Assessment, Management, and Prevention*, as a testament to the collaborative expertise of an internationally renowned and diverse group of experts in the field of aging and frailty. This collective effort not only reflects a unique journey but also underscores the scientific foundation and clinical and educational implications embedded in the meticulous crafting of this work. As we stand on an era marked by an unprecedented demographic shift towards an aging population, the study of frailty emerges as a critical frontier in healthcare. Frailty, a complex and multifaceted condition, embodies the vulnerability and diminished physiological reserve that often accompanies the aging process. It transcends mere chronological age, encompassing a spectrum of physical, psychological, and social dimensions. In the context of this profound demographic transformation, the book *Frailty: A Multidisciplinary Approach to Assessment, Management, and Prevention* assumes heightened significance.

As we traverse the intricate landscape of frailty, it becomes apparent that a multidisciplinary perspective is not just valuable but indispensable. This book has been meticulously shaped to encapsulate the wealth of knowledge and nuanced insights of our esteemed contributors, who serve as prominent figures in their respective disciplines. Their routes of expertise converge from various corners of the globe, presenting readers with a panoramic view of frailty that transcends geographical and disciplinary boundaries.

Embarking on a comprehensive exploration, this book unfolds through curated parts, each encapsulating a unique facet of the intricate complexity that is frailty. In “Frailty and Related Concepts: An Overview,” a robust foundation is laid, offering an in-depth understanding of the complexities inherent in frailty, emphasizing the scientific basis that underscores its multifaceted nature. In the “Mechanisms: Pathogenesis and Research” part, contributors’ expertise converges to unveil the intricate mechanisms shaping our comprehension of frailty’s origins, providing a deeper insight into the underpinnings of this multifaceted condition and its scientific underpinnings. The part on “Assessment” offers readers a comprehensive examination of assessment tools, methodologies, and advancements from diverse perspectives, showcasing the clinical implications for practitioners and educators alike. Moving onward, “Management: Treatment and Prevention” presents a valuable exploration of approaches to managing, treating, and preventing frailty, drawing on the well-traveled routes of expert contributors to enhance overall well-being. The “Settings of Care” part reflects contextual richness through contributors’ varied experiences, addressing frailty in different care settings and providing a wealth of multidisciplinary insights crucial for clinical application. The “Other Conditions” part traverses interconnected landscapes of health, unraveling the intricate relationships between frailty and other healthcare conditions, thus presenting readers with a comprehensive view of complex health scenarios. Finally, “Social and Other Issues” transcends clinical boundaries as contributors navigate societal, contextual, and educational dimensions of frailty, providing a holistic understanding enriched by diverse perspectives with implications for clinical practice, educational, and healthcare policy endeavors. Together, these parts form a cohesive narrative, weaving together the broad range of expertise of contributors to present readers with a nuanced and multidimensional exploration of frailty across various dimensions of aging.

This collaborative endeavor is a testament to the collective wisdom and expertise of our contributors, who have embarked on a journey not only to advance the understanding of frailty but also to provide a scientific basis and offer invaluable clinical, educational, and policy insights. We envision this book as a beacon of knowledge, guiding healthcare professionals, researchers, and policymakers through the multidisciplinary routes that lead to a more comprehensive understanding of frailty, thereby enriching both scientific discourse and practical applications in clinical, educational, and healthcare policy settings.

Hollywood, FL, USA
Halifax, NS, Canada

Jorge G. Ruiz
Olga Theou

Contents

Part I Frailty and Related Concepts: An Overview

1 The Frailty Phenotype	3
Jorge G. Ruiz and Sara Espinoza	
2 Deficit Accumulation	11
Samuel D. Searle and Kenneth Rockwood	
3 Prevalence, Incidence, and Risk Factors of Frailty	15
Gotaro Kojima, Reijiro Aoyama, and Steve Iliffe	
4 Integration: A Unified Frailty Framework	19
Domenico Azzolino and Matteo Cesari	
5 Intrinsic Capacity	23
Catherine Takeda, Philippe De Souto Barreto, and Bruno Vellas	
6 Transitions, Trajectories, and Reversibility	31
Ariela Orkaby and Rachel E. Ward	
7 Sarcopenia and Frailty: A Common Thread Across Multiple Comorbidities	39
K. Prokopidis, J. Hargreaves, and T. Ispoglou	
8 Complications of Frailty	45
Luis Miguel Gutiérrez Robledo and Mario Ulises Pérez Zepeda	
9 Sex Differences and Frailty	51
Myles W. O'Brien and Judith Godin	

Part II Mechanisms: Pathogenesis and Research

10 Inflammaging and Immunosenescence	57
Tamàs Fülöp, G. Pawelec, A. A. Cohen, V. Legault, K. Hirokawa, A. Larbi, A. Khalil, C. Franceschi, and J. M. Witkowski	
11 Implications of the Exposome for Frailty	73
Paulo H. M. Chaves and Marcia H. Varella	
12 Preclinical Models of Frailty	81
Manish Mishra and Susan E. Howlett	
13 Biomarkers of Frailty	91
Mariam El Assar, Isabel Rodriguez-Sanchez, Alejandro Álvarez-Bustos, and Leocadio Rodríguez-Mañás	

14	Mitochondrial Alterations and Signaling in Aging, Frailty, and Sarcopenia: An Integrated View	103
	Anna Picca, Marta Gonzalez-Freire, Stephen D. Anton, Emanuele Marzetti, and Christiaan Leeuwenburgh	
15	Human Microbiome and Frailty: From Observations of Clinically Relevant Associations to Insights into Biological Mechanisms	109
	Peter J. Larson, Wei Zhou, Julie Robison, George A. Kuchel, and Julia Oh	
Part III Assessment		
16	Clinical Frailty Scale	121
	Kenneth Rockwood and Olga Theou	
17	Frailty Measure Development, Selection, and Implications	125
	Karen Bandeen-Roche	
18	Pictorial Fit-Frail Scale	131
	Olga Theou and Kenneth Rockwood	
19	Frailty Assessment: The FRAIL Scale	137
	Angela M. Sanford and John E. Morley	
20	Edmonton Frail Scale	143
	Darryl B. Rolfson	
21	The Tilburg Frailty Indicator (TFI)	145
	Robbert J. J. Gobbens	
22	The Study of Osteoporotic Fractures (SOF) Frailty Index	151
	Kristine E. Ensrud	
23	Physical Assessments Instruments	157
	M. Aubertin-Leheudre and F. Buckinx	
24	Technology-Based Assessments of Frailty	167
	Megan Huisingsh-Scheetz, Nabiel Mir, M. Lucia Madariaga, and Daniel Rubin	
25	Frailty Tools Using Health Care Databases	173
	Stephanie Denise M. Sison and Dae Hyun Kim	
Part IV Management: Treatment and Prevention		
26	Comprehensive Geriatric Assessment CGA	181
	Wakana Teranaka and Simon Conroy	
27	Exercise Strategies for Improving Health Outcomes in Older Adults with Comorbidities: The Role of Vivifrail Tailored-Multicomponent Training	187
	Mikel Izquierdo	
28	Nutritional Aspects of Frailty in Older Adults: Undernutrition, Nutrients Consumption, and Diet Patterns	201
	Hélio José Coelho-Junior and Emanuele Marzetti	
29	Deprescribing	211
	Sarah N. Hilmer and Nashwa Masnoon	

30	Geroscience-Based Interventions	217
	Oh Sung Kwon and Sara Espinoza	
31	Integrated Care for Frailty	223
	Anne Hendry, Ronan O’Caoimh, Mohamed A. Salem, Ana Carriazo, and Regina Roller-Wirnsberger	
Part V Settings of Care		
32	Frailty in Primary Care: Interventions and Opportunities	231
	John Travers, Marie Therese Cooney, and Roman Romero-Ortuno	
33	Frailty in Acute Care Settings	239
	Natasha Melo Resendes	
34	Frailty in Nursing Homes	249
	Renuka Visvanathan	
35	Rehabilitation	255
	Margaret Danilovich	
36	Palliative Care	259
	Daniel Stow, Sarah Combes, and Felicity Dewhurst	
37	Frailty in Home Care	267
	Carmen Castillo Gallego	
38	A Community-Based Model for Detecting and Managing Frailty	273
	Jean Woo, Ruby Yu, and Anson Kai-Chun Chau	
Part VI Other Conditions		
39	Bidirectional Relationships Between COVID-19 and Frailty in Older Adults	281
	Chia-Ling Kuo, Patrick P. Coll, and George A. Kuchel	
40	Frailty and Cancer	287
	Marco Ruiz, Natasha Melo Resendes, and Jannelle Vicens	
41	Frailty and Cardiovascular Disease	299
	Deirdre E. O’Neill and Daniel E. Forman	
42	Frailty in Older People with Diabetes Mellitus	309
	Alan J. Sinclair and A. H. Abdelhafiz	
43	Frailty and Cognition. Fellow Travelers or Partners in Crime?	325
	Manuel Montero-Odasso, Frederico Pieruccini-Faria, Qu Tian, and Joe Verghese	
44	Frailty and Orthogeriatrics: Enhancing Care for Fragility Fractures	333
	Mauricio Vazquez-Guajardo and Gustavo Duque	
45	Frailty in Older Adults with Obesity and the Effect of Lifestyle Interventions	345
	Georgia Colleluori and Dennis T. Villareal	
46	Vaccines, Vaccine-Preventable Diseases, and Frailty	351
	Henrique Pott and Melissa K. Andrew	

47 Oral Health and Frailty	359
Christie-Michele Hogue and Roberto Carlos Castrejón-Pérez	
48 Perioperative, Surgical, and Procedural Care for Older Adults with Frailty	369
Daniel I. McIsaac and Sylvie D. Aucoin	
49 Delirium	377
Giuseppe Bellelli, Maria Cristina Ferrara, and Alessandro Morandi	
Part VII Social and Other Issues	
50 Social Determinants of Physical Frailty	389
Brian Buta, Erica Twardzik, Laura Samuel, Thomas Cudjoe, Anthony L. Teano, Jackie Langdon, Roland J. Thorpe Jr, Jeremy Walston, and Qian-Li Xue	
51 Educating and Training the Workforce	403
Iriana S. Hammel and Elizabeth N. Chapman	
52 Frailty in Low- and Middle-Income Countries	411
Tania Tello, Ximena Guevara, and Paola Casas	
53 Ethical and Policy Aspects of Frailty	419
John Muscedere	
Index	425

Frailty and Related Concepts: An Overview



The Frailty Phenotype

1

Jorge G. Ruiz and Sara Espinoza

Background

This chapter examines the frailty phenotype, an integral concept in geriatric healthcare introduced by Dr. Linda Fried and collaborators in 2001 [1]. This paradigm has transformed our approach to identifying and managing frailty in older adults, presenting a methodical framework for screening, evaluation and intervention. We begin by reviewing the operational definition of frailty according to the frailty phenotype, which is identified by meeting at least three out of five criteria: unintentional weight loss, self-reported exhaustion, muscular weakness, reduced gait speed, and low physical activity [1, 2]. This definition signifies a notable departure from the traditional view of aging as a mere time-related decline, instead acknowledging frailty as a specific medical condition and geriatric syndrome [3–5]. Progressing through the chapter, we will analyze how older adults are categorized as “frail” or “pre-frail,” underscoring its clinical significance. We aim to elucidate how this classification facilitates early intervention, influences clinical decision-making, and directs the customization of therapeutic strategies for older adults.

The conceptualization and implementation of the frailty phenotype in the field of geriatric medicine is in constant flux. Later in this chapter, we address some of the criticisms aimed at this framework, including its focus on physical aspects, and the attendant omission of cognitive, psychological, and social dimensions of frailty. We will review research aimed at the frailty phenotype, providing a more encompassing viewpoint on an older individual’s health. Additionally, we will attempt to address the challenges faced when implementing this framework in various clinical settings, stressing

the need for a standardization of assessment techniques, a more holistic viewpoint of the frailty phenotype conceptualization, its significance in geriatric care, and the potential avenues for its future advancement.

The Concept of Frailty Before Fried

Prior to a more formal conceptualization of frailty using the frailty phenotype [1] and the deficit accumulation model [6], the notion of frailty in older adults was progressively becoming a key area of discussion in geriatric circles. During the 1950s and 1960s, the term “frailty” started receiving more attention and this movement only grew by the 1980s and 1990s [3, 5, 7, 8]. The Federal Council on Aging in the United States coined the terms “frail elderly [Sic]” in 1978, specifically referring to older adults, typically those above 75 years, who were usually high users of healthcare services due to the concurrence of medical and psychological multimorbidity [9]. These initial characterizations recognized frailty as a decrease in both physical and cognitive abilities, leading to increased vulnerability, but a critical interpretation was that frailty was not considered a necessary consequence of the aging process. The term was then broadly applied to describe a wide range of clinical conditions related to aging, including physical debility, susceptibility to illnesses, and a general decline in health, yet still lacking a cohesive, operational definition [4, 10].

In this early phase, the perception of frailty was seen as that of a multi-domain concept, representing the interplay of physical, mental, and social factors on an individual’s health [11]. Key elements such as social withdrawal and

J. G. Ruiz (✉)
Memorial Healthcare System, Hollywood, FL, USA
e-mail: jorgeruiz@mhs.net

S. Espinoza
Center for Translational Geroscience, Diabetes and Aging Center,
Department of Medicine, Cedars-Sinai Medical Center,
Los Angeles, CA, USA
e-mail: sara.espinoza@cshs.org

mental health issues, including depression, were identified as contributing factors to frailty [12]. The prevailing clinical approach to frailty at this time was centered on the management of specific symptoms and health issues, rather than a comprehensive approach to the management of the frailty syndrome [3, 13]. Research in this period, although not as targeted as in later years, played a crucial role in shaping our understanding of frailty, with studies focusing on aging and susceptibility to health challenges. Comprehensive geriatric assessments were instrumental in the health evaluation of older adults during this time, but these assessments did not distinctly focus on frailty as a separate condition [14–16].

The Origins of the Frailty Phenotype: The Cardiovascular Health Study

Dr. Linda P. Fried's first formulation of the frailty phenotype concept occurred within the context of the Cardiovascular Health Study (CHS) marking a pivotal moment in the field of aging and geriatric medicine [1]. This study, a comprehensive and multicenter observational effort started in the late 1980s in the United States, was primarily designed at the identification of risk factors for cardiovascular diseases and strokes in older adults [17]. It was in this setting that Dr. Fried and her collaborators began pioneering research on frailty, using the CHS broad dataset from participants over 65 years old, encompassing detailed assessments, and various health indicators [1, 17, 18].

Dr. Fried and her team performed a broad analysis of CHS data, identifying specific, measurable characteristics that could consistently indicate frailty [1]. They identified five key criteria: unintentional weight loss, self-reported exhaustion, muscular weakness (assessed via handgrip strength), reduced walking speed, and decreased physical activity. The presence of these criterion in various combinations was associated with health outcomes relevant to older adults like falls, acute care hospitalizations, disabilities, and death [1, 2].

A pioneering aspect of Dr. Fried's approach was the formulation of an operational definition of frailty, classified as meeting at least three of these criteria. A related concept of "pre-frailty," defined by one or two criteria, was also formulated, allowing for an early identification and the possibility of the development and implementation of preventive measures to forestall the onset of frailty [1, 2]. This approach to frailty proved effective in predicting adverse health outcomes and quickly gained acceptance in geriatric medicine, providing cli-

nicians a valuable tool to identify and aid frail older adults [19].


Biological Underpinnings of the Frailty Phenotype

The frailty phenotype, as conceptualized by Fried and colleagues, is underpinned by a complex biological and pathophysiological framework, adding scientific substantiation to its five clinical criteria [20–23]. This phenotype emerges from a dysregulated complex dynamical system in the older adult, involving an array of modular systems and subsystems [23, 24]. These systems normally operate both autonomously and collectively, utilizing feedforward and feedback mechanisms to regulate allostasis and homeostasis [23, 25]. In cases of physical frailty, however, there's a collective failure in these core regulatory systems, leading to pronounced dysfunction under stress [26]. This results in a state of frailty characterized by reduced overall functionality, with a nonlinear relationship between the level of physiological dysfunction and the severity of frailty. A critical threshold exists, beyond which a reduced functional state is unsustainable [23].

Physically frail individuals exhibit dysfunction in crucial systems like metabolism, musculoskeletal structure, and stress response [23]. This manifests as disrupted energy metabolism, including altered glucose-insulin dynamics and hormonal imbalances [27, 28], as well as compromised musculoskeletal [29] and mitochondrial functions [30]. Additionally, the stress-response system is adversely affected, evidenced by heightened inflammation, autonomic nervous system dysregulation, and hypothalamic-pituitary-adrenal (HPA) axis imbalances [31, 32]. These dysregulated systems impair the ability of frail individuals to adequately respond to environmental challenges, underlining a set of pathophysiological traits central to physical frailty [23].

This concept is visually depicted in Fig. 1.1 [23], which illustrates physical frailty as a syndrome arising from a hierarchy of interconnected physiological and cellular systems. Key physiological systems critical to frailty are shown as gold circles, with their subcomponents as orange ovals. Cellular changes due to aging, represented by purple ovals, are thought to trigger dysfunction in these physiological systems. This dysfunction, indicated by a dark orange oval, is directly linked to the physical frailty phenotype, positioned at the apex of the model. This schema underscores the multi-layered nature of frailty, emphasizing its roots in both cellular alterations and systemic interactions [23].

Fig. 1.1 A hierarchical, multiscale representation of the physiological dysregulation and likely biological drivers of physical frailty. Fried LP, Cohen AA, Xue QL, Walston J, Bandeen-Roche K, Varadhan R. The physical frailty syndrome as a transition from homeostatic symphony to cacophony. *Nature aging*. 2021 Jan;1(1):36–46








Frailty Phenotype Criteria

Continuing from our introduction to the frailty phenotype framework, we will now explore the specific criteria that form its foundation (Fig. 1.2). These criteria are crucial for the identification and classification of older adults as “frail” or “pre-frail,” offering a solid base for clinical evaluation and intervention [1, 2]. Unintended Weight Loss is identified when an individual experiences a loss of more than 4.5 kg (10 pounds) or over 5% of their body weight within a year, serving as a critical marker of frailty. This significant reduction highlights a decline in muscle mass and overall vigor, which are essential for the health and functionality of seniors. Self-Reported exhaustion is assessed through subjective evaluations of an individual’s energy levels and motivation. Muscular Weakness is evaluated using handgrip strength as measured with a portable dynamometer. This assessment, adjusted for sex and body size, provides a measure of an individual’s muscular strength. Slowness is observed through a reduction in gait speed, quantified by measuring walking speed over 4 m. This metric, adjusted for sex and stature,

serves as a direct indicator of an individual’s mobility and overall physical capabilities. Low physical activity is determined by self-reported levels of activity using the short version of Minnesota Leisure Time Activity, which estimates activity in kcal/kg, with adjustments made for sex to fairly compare an individual’s activity against established benchmarks. These criteria help in assessing the extent of an individual’s engagement in physical activities relative to normative standards.

An individual meeting three or more of these criteria is deemed “frail,” displaying a heightened susceptibility to detrimental health outcomes such as falls, hospitalization, disability, and mortality [1]. Those matching one or two criteria fall into the “pre-frail” category, indicating a moderate risk and potential for developing significant frailty. It is essential to recognize that while this frailty definition is widely recognized, the frailty concept itself can differ in various research and clinical contexts [33]. Together, these indicators provide a comprehensive framework for identifying and addressing frailty in older adults, focusing on key areas of health and functionality to improve their quality of life.

Unintended Weight Loss	Exhaustion	Weakness	Slowness	Low Physical Activity
4.5 kg or more than 5% of body weight within a year	Self-Report (2 questions from the CES-D)	Jamar Handgrip dynamometer	Gait speed in meters/second (over 4 meters)	Short version of Minnesota Leisure Time Activity-Kcal/Kg
				

Robust: 0 criteria; Pre-Frail: 1-2 criteria; Frail: 3 or more criterion

Fried LP et al. Frailty in older adults: evidence for a phenotype. *J Gerontol A Biol Sci Med Sci* 2001; **56**: M146–56.

Fig. 1.2 The five frailty phenotype criteria

Application of the Frailty Phenotype in Research

Since its development by Dr. Fried and her team, the frailty phenotype has become a cornerstone in geriatric research, forming the basis of numerous studies on older adult health and well-being [1, 34]. Its clarity and operational criteria have allowed for a more uniform approach to frailty research across different populations and environments. Researchers have used this framework to examine the biological aspects of frailty and assess the impact of various interventions aimed at its prevention or mitigation [19].

In the field of epidemiology, the frailty phenotype has become a useful conceptual framework for the investigation of frailty-related risk factors and their progression [35]. These studies have shed light on the influence of lifestyle, health conditions, race, ethnicity, and other social-economic factors on frailty's development and course in older individuals [36–39]. The phenotype has also been integral in clinical trials testing both pharmacological and non-pharmacological strategies, ranging from exercise and nutrition programs to new medications, all aimed at enhancing outcomes for frail populations [40–43].

Moreover, the frailty phenotype has encouraged a broader perspective in geriatric research, highlighting the need to consider psychological, social, and environmental factors alongside physical aspects of aging [44, 45]. This comprehensive approach has deepened our understanding of aging and opened new pathways for intervention and policy formulation to improve older adults' quality of life [46].

Advantages and Disadvantages

The frailty phenotype model, known for its precise and pragmatic methodology, is particularly noteworthy in this regard. Its straightforwardness renders it highly effective in clinical and research environments [47]. These criteria are not chosen arbitrarily; they are solidly linked to negative health outcomes in older adults through empirical evidence [48, 49]. A strength of this model lies in its focus on observable physical dimensions of frailty, critical in the prediction of clinically relevant outcomes like falls, hospitalizations, physical disabilities, and death [47]. The frailty phenotype, applicable at first contact, effectively categorizes individuals as robust, pre-frail, or frail for an initial risk assessment [44]. The frailty phenotype indicators are invaluable in spotting individuals at risk, aiding in the prevention and management of age-related decline [50]. Additionally, the model's ability to identify "pre-frail" individuals allows for early intervention, potentially delaying or even reversing the future onset of frailty [47, 51]. This proactive approach can assist clinicians and researchers in the development, implementation, and evaluation of targeted measures aimed at improving quality of life, reduce the burden of multimorbidity and functional decline, reduce healthcare costs, and potentially prolong survival.

The frailty phenotype model, despite its solid grounding in research, presents several limitations. The frailty phenotype has seen limited uptake in routine clinical practice, due to several challenges [46]. The complexity and time constraints in clinical environments, especially in primary care and acute hospital settings, hinder its integration into daily practice [52,

53]. The requirement for specific measurements like grip strength and walking speed demands time commitments, training, and specialized equipment, which may limit its routine use in busy clinical practices [44, 46]. Another barrier is the varying levels of training and awareness among healthcare professionals [54, 55]. While the concept of frailty is widely recognized, comprehensive understanding and application of the frailty phenotype are not uniformly incorporated into medical training or professional development curricula [56]. Additionally, the emphasis on physical criteria in the frailty phenotype may cause clinicians to neglect other vital aspects of frailty, such as cognitive and psychosocial elements [57, 58]. This narrow scope may lead to an under-recognition of frailty in individuals who do not meet its stringent criteria. Compounding these issues is the reported variability in how the frailty phenotype is applied across different studies, resulting in marked inconsistencies in the reported prevalence of frailty, and the model's ability to predict clinical outcomes. The frequent adaptations or modifications of the original criteria as reported in the literature further impact the reliability and comparability of research outcomes [33].

Overall, the frailty phenotype model is helpful at identifying older adults at risk of falls, hospitalizations, disabilities, and death by categorizing them as robust, pre-frail, or frail. Its evidence-based, physical-focused criteria are critical for early, targeted interventions, potentially improving healthcare outcomes. However, its implementation in clinical practice faces challenges due to complexity, time constraints, the need for specific measurements and instrumentation, and training of healthcare professionals. The model's physical criteria emphasis may also overlook cognitive and psychosocial frailty aspects, limiting its comprehensive application.

Future Directions

Moving forward, the frailty phenotype model's role in geriatric care could be enhanced by addressing several areas:

Standardization of Criteria: The lack of standardization in the frailty phenotype criteria may lead to misclassification and the adjudication of incorrect clinical risks, leading to inappropriate management strategies for older individuals [59, 60]. To improve predictive accuracy and ensure the effectiveness of interventions, it is critical to tailor the criteria to the population's specific phenotypic traits. Addressing these challenges requires further research to refine assessment tools for broader applicability across various care settings.

Integration of Other Domains: The incorporation of cognitive and mental health domains into the frailty phenotype would provide a more comprehensive estimation to frailty. This holistic approach could lead to improved assessment and management outcomes for the older adult population [57].

Technological Advancements in Assessment: Employing emergent information technologies, like wearable devices, for example, widely available smart watches, could offer continuous monitoring of key indicators (gait speed, levels of physical activity and exercise), leading to more unobtrusive, efficient, accurate, and timely frailty detection and intervention [61, 62].

Education and Training: Enhancing healthcare professionals' understanding and use of the frailty phenotype through comprehensive training including the incorporation of the frailty phenotype into medical curricula could improve frailty identification and management, extending this training to interprofessional teams involved in the care of older adults [46, 63].

Policy and System Integration: Embedding the frailty phenotype into health policies and systems, including guidelines and protocols for assessment in various healthcare settings at the point of care or as part of population health, electronic health records, among others, could lead to better value-based care and better resource allocation for the growing aging population [46, 64].

Conclusions

In this chapter, we have reviewed the frailty phenotype, a transformative concept in geriatric healthcare introduced by Dr. Linda Fried and colleagues in 2001. This framework has revolutionized the way frailty is identified and managed in older adults, offering a clear operational definition based on five key criteria: unintentional weight loss, reported fatigue, muscle weakness, reduced gait velocity, and low physical activity. This approach represents a significant shift from traditional perceptions of aging as a mere time-related decline, highlighting frailty as a distinct geriatric syndrome. Despite its impact, the chapter also addresses the limitations of the frailty phenotype, particularly its focus on physical dimensions while often overlooking cognitive, psychological, and social factors. We discussed ongoing research efforts to expand the frailty concept and discussed the challenges faced in integrating this framework into clinical practice, emphasizing the importance of standardized assessment techniques and training for healthcare providers. Overall, this chapter provided a comprehensive overview of the frailty phenotype, underlining its pivotal role in the care of older adults.

References

1. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. *J Gerontol A Biol Sci Med Sci*. 2001;56(3):146–56.
2. Fried LP, Ferrucci L, Darer J, Williamson JD, Anderson G. Untangling the concepts of disability, frailty, and comorbidity:

- implications for improved targeting and care. *J Gerontol A Biol Sci Med Sci.* 2004;59(3):255–63.
3. Rockwood K, Fox RA, Stolee P, Robertson D, Beattie BL. Frailty in elderly people: an evolving concept. *CMAJ.* 1994;150(4):489–95.
 4. Campbell AJ, Buchner DM. Unstable disability and the fluctuations of frailty. *Age Ageing.* 1997;26(4):315–8.
 5. Hamerman D. Toward an understanding of frailty. *Ann Intern Med.* 1999;130(11):945–50.
 6. Rockwood K, Mitnitski A. Frailty in relation to the accumulation of deficits. *J Gerontol A Biol Sci Med Sci.* 2007;62(7):722–7.
 7. Fried LP. Conference on the physiologic basis of frailty. April 28, 1992, Baltimore, Maryland, U.S.A. Introduction. *Ageing.* 1992;4(3):251–2.
 8. Woodhouse KW, O'Mahony MS. Frailty and ageing. *Age Ageing.* 1997;26(4):245–6.
 9. Lewis D. Public policy and the frail elderly: a staff report. 1978.
 10. Powell C. Frailty: help or hindrance? *J R Soc Med.* 1997;90(32):23–6.
 11. Rockwood K, Stolee P, McDowell I. Factors associated with institutionalization of older people in Canada: testing a multifactorial definition of frailty. *J Am Geriatr Soc.* 1996;44(5):578–82.
 12. Strawbridge WJ, Shema SJ, Balfour JL, Higby HR, Kaplan GA. Antecedents of frailty over three decades in an older cohort. *J Gerontol B Psychol Sci Soc Sci.* 1998;53(1):S9–16.
 13. Rockwood K. Medical management of frailty: confessions of a gnostic. *CMAJ.* 1997;157(8):1081–4.
 14. Rubenstein LZ, Siu AL, Wieland D. Comprehensive geriatric assessment: toward understanding its efficacy. *Ageing.* 1989;1(2):87–98.
 15. Siu AL, Kravitz RL, Keeler E, Hemmerling K, Kington R, Davis JW, et al. Postdischarge geriatric assessment of hospitalized frail elderly patients. *Arch Intern Med.* 1996;156(1):76–81.
 16. Rockwood K, Silivius JL, Fox RA. Comprehensive geriatric assessment. Helping your elderly patients maintain functional well-being. *Postgrad Med.* 1998;103(3):247–9.
 17. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, et al. The cardiovascular health study: design and rationale. *Ann Epidemiol.* 1991;1(3):263–76.
 18. Fried LP, Kronmal RA, Newman AB, Bild DE, Mittelmark MB, Polak JF, et al. Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study. *JAMA.* 1998;279(8):585–92.
 19. Buta BJ, Walston JD, Godino JG, Park M, Kalyani RR, Xue QL, et al. Frailty assessment instruments: systematic characterization of the uses and contexts of highly-cited instruments. *Ageing Res Rev.* 2016;26:53–61.
 20. Walston JD. Connecting age-related biological decline to frailty and late-life vulnerability. *Nestle Nutr Inst Workshop Ser.* 2015;83:1–10.
 21. Walston J, McBurnie MA, Newman A, Tracy RP, Kop WJ, Hirsch CH, et al. Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: results from the Cardiovascular Health Study. *Arch Intern Med.* 2002;162(20):2333–41.
 22. Walston J, Bandeen-Roche K, Buta B, Bergman H, Gill TM, Morley JE, et al. Moving frailty toward clinical practice: NIA intramural frailty science symposium summary. *J Am Geriatr Soc.* 2019;67(8):1559–64.
 23. Fried LP, Cohen AA, Xue QL, Walston J, Bandeen-Roche K, Varadhan R. The physical frailty syndrome as a transition from homeostatic symphony to cacophony. *Nat Aging.* 2021;1(1):36–46.
 24. Ghachem A, Fried LP, Legault V, Bandeen-Roche K, Presse N, Gaudreau P, et al. Evidence from two cohorts for the frailty syndrome as an emergent state of parallel dysregulation in multiple physiological systems. *Biogerontology.* 2021;22(1):63–79.
 25. Varadhan R, Walston JD, Bandeen-Roche K. Can a link be found between physical resilience and frailty in older adults by studying dynamical systems? *J Am Geriatr Soc.* 2018;66(8):1455–8.
 26. Walston J, Hadley EC, Ferrucci L, Guralnik JM, Newman AB, Studenski SA, et al. Research agenda for frailty in older adults: toward a better understanding of physiology and etiology: summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults. *J Am Geriatr Soc.* 2006;54(6):991–1001.
 27. Kalyani RR, Varadhan R, Weiss CO, Fried LP, Cappola AR. Frailty status and altered dynamics of circulating energy metabolism hormones after oral glucose in older women. *J Nutr Health Aging.* 2012;16(8):679–86.
 28. Kalyani RR, Varadhan R, Weiss CO, Fried LP, Cappola AR. Frailty status and altered glucose-insulin dynamics. *J Gerontol A Biol Sci Med Sci.* 2012;67(12):1300–6.
 29. Weiss CO, Hoenig HH, Varadhan R, Simonsick EM, Fried LP. Relationships of cardiac, pulmonary, and muscle reserves and frailty to exercise capacity in older women. *J Gerontol A Biol Sci Med Sci.* 2010;65(3):287–94.
 30. Ferrucci L, Zampino M. A mitochondrial root to accelerated ageing and frailty. *Nat Rev Endocrinol.* 2020;16(3):133–4.
 31. Gaffey AE, Bergeman CS, Clark LA, Wirth MM. Aging and the HPA axis: stress and resilience in older adults. *Neurosci Biobehav Rev.* 2016;68:928–45.
 32. Le NP, Varadhan R, Fried LP, Cappola AR. Cortisol and dehydroepiandrosterone response to adrenocorticotrophic hormone and frailty in older women. *J Gerontol A Biol Sci Med Sci.* 2021;76(5):901–5.
 33. Theou O, Cann L, Blodgett J, Wallace LM, Brothers TD, Rockwood K. Modifications to the frailty phenotype criteria: systematic review of the current literature and investigation of 262 frailty phenotypes in the Survey of Health, Ageing, and Retirement in Europe. *Ageing Res Rev.* 2015;21:78–94.
 34. Walston J, Robinson TN, Ziemann S, McFarland F, Carpenter CR, Althoff KN, et al. Integrating frailty research into the medical specialties-report from a U13 conference. *J Am Geriatr Soc.* 2017;65(10):2134–9.
 35. Collard RM, Boter H, Schoevers RA, Oude Voshaar RC. Prevalence of frailty in community-dwelling older persons: a systematic review. *J Am Geriatr Soc.* 2012;60(8):1487–92.
 36. Espinoza SE, Fried LP. Risk factors for frailty in the older adult. *Clin Geriatr.* 2007;15(6):37.
 37. Espinoza SE, Hazuda HP. Frailty in older Mexican-American and European-American adults: is there an ethnic disparity? *J Am Geriatr Soc.* 2008;56(9):1744–9.
 38. Espinoza SE, Hazuda HP. Frailty prevalence and neighborhood residence in older Mexican Americans: the San Antonio longitudinal study of aging. *J Am Geriatr Soc.* 2015;63(1):106–11.
 39. Feng Z, Lugtenberg M, Franse C, Fang X, Hu S, Jin C, et al. Risk factors and protective factors associated with incident or increase of frailty among community-dwelling older adults: a systematic review of longitudinal studies. *PLoS One.* 2017;12(6):e0178383.
 40. Espinoza SE, Jiwani R, Wang J, Wang CP. Review of interventions for the frailty syndrome and the role of metformin as a potential pharmacologic agent for frailty prevention. *Clin Ther.* 2019;41(3):376–86.
 41. Espinoza SE, Orsak B, Wang CP, MacCarthy D, Kellogg D, Powers B, et al. An individualized low-intensity walking clinic leads to improvement in frailty characteristics in older veterans. *J Frailty Aging.* 2019;8(4):205–9.
 42. Espinoza SE, Musi N, Wang CP, Michalek J, Orsak B, Romo T, et al. Rationale and study design of a randomized clinical trial of metformin to prevent frailty in older adults with prediabetes. *J Gerontol A Biol Sci Med Sci.* 2020;75(1):102–9.
 43. Espinoza SE, Woods RL, Ekram A, Ernst ME, Polekhina G, Wolfe R, et al. The effect of low-dose aspirin on frailty phenotype and frailty index in community-dwelling older adults in the aspirin in

- reducing events in the elderly study. *J Gerontol A Biol Sci Med Sci*. 2022;77(10):2007–14.
44. Cesari M, Gambassi G, van Kan GA, Vellas B. The frailty phenotype and the frailty index: different instruments for different purposes. *Age Ageing*. 2014;43(1):10–2.
 45. Xue QL, Buta B, Ma L, Ge M, Carlson M. Integrating frailty and cognitive phenotypes: why, how, now what? *Curr Geriatr Rep*. 2019;8(2):97–106.
 46. Kojima G, Liljas AEM, Iliffe S. Frailty syndrome: implications and challenges for health care policy. *Risk Manag Healthc Policy*. 2019;12:23–30.
 47. Xue QL. The frailty syndrome: definition and natural history. *Clin Geriatr Med*. 2011;27(1):1–15.
 48. Xue QL, Tian J, Walston JD, Chaves PHM, Newman AB, Bandeen-Roche K. Discrepancy in frailty identification: move beyond predictive validity. *J Gerontol A Biol Sci Med Sci*. 2020;75(2):387–93.
 49. Kim DJ, Massa MS, Potter CM, Clarke R, Bennett DA. Systematic review of the utility of the frailty index and frailty phenotype to predict all-cause mortality in older people. *Syst Rev*. 2022;11(1):187.
 50. Dent E, Morley JE, Cruz-Jentoft AJ, Woodhouse L, Rodriguez-Manas L, Fried LP, et al. Physical frailty: ICF SR International Clinical Practice Guidelines for identification and management. *J Nutr Health Aging*. 2019;23(9):771–87.
 51. Xue QL, Bandeen-Roche K, Varadhan R, Zhou J, Fried LP. Initial manifestations of frailty criteria and the development of frailty phenotype in the Women's Health and Aging Study II. *J Gerontol A Biol Sci Med Sci*. 2008;63(9):984–90.
 52. Allison R, Assadzandi S, Adelman M. Frailty: evaluation and management. *Am Fam Physician*. 2021;103(4):219–26.
 53. Bahat G, Ilhan B, Tufan A, Dogan H, Karan MA. Success of simpler modified fried frailty scale to predict mortality among nursing home residents. *J Nutr Health Aging*. 2021;25(5):606–10.
 54. Cesari M, Vellas B. Frailty in clinical practice. *Frailty*. 2015;83:93–8.
 55. Obbia P, Graham C, Duffy FJR, Gobbens RJJ. Preventing frailty in older people: an exploration of primary care professionals' experiences. *Int J Older People Nursing*. 2020;15(2):e12297.
 56. Abyad A. Is primary health care capable of addressing frailty? *Eur Geriatr Med*. 2021;12(5):899–902.
 57. Avila-Funes JA, Amieva H, Barberger-Gateau P, Le Goff M, Raoux N, Ritchie K, et al. Cognitive impairment improves the predictive validity of the phenotype of frailty for adverse health outcomes: the three-city study. *J Am Geriatr Soc*. 2009;57(3):453–61.
 58. Vella Azzopardi R, Beyer I, Vermeiren S, Petrovic M, Van Den Noortgate N, Bautmans I, et al. Increasing use of cognitive measures in the operational definition of frailty—a systematic review. *Ageing Res Rev*. 2018;43:10–6.
 59. Alonso Bouzon C, Carnicero JA, Turin JG, Garcia-Garcia FJ, Esteban A, Rodriguez-Manas L. The standardization of frailty phenotype criteria improves its predictive ability: The Toledo Study for Healthy Aging. *J Am Med Dir Assoc*. 2017;18(5):402–8.
 60. Boreskie KF, Kehler DS, Costa EC, Hiebert BM, Hamm NC, Moffatt TL, et al. Standardization of the Fried frailty phenotype improves cardiovascular disease risk discrimination. *Exp Gerontol*. 2019;119:40–4.
 61. Zhou H, Razjouyan J, Halder D, Naik AD, Kunik ME, Najafi B. Instrumented trail-making task: application of wearable sensor to determine physical frailty phenotypes. *Gerontology*. 2019;65(2):186–97.
 62. Park C, Mishra R, Golledge J, Najafi B. Digital biomarkers of physical frailty and frailty phenotypes using sensor-based physical activity and machine learning. *Sensors*. 2021;21:16.
 63. Ruiz JG, Dent E, Morley JE, Merchant RA, Beilby J, Beard J, et al. Screening for and managing the person with frailty in primary care: ICF SR consensus guidelines. *J Nutr Health Aging*. 2020;24(9):920–7.
 64. Cesari M, Prince M, Thiyagarajan JA, De Carvalho IA, Bernabei R, Chan P, et al. Frailty: an emerging public health priority. *J Am Med Dir Assoc*. 2016;17(3):188–92.



Deficit Accumulation

2

Samuel D. Searle and Kenneth Rockwood

Historical Background/Origins

With ageing, people and most species accumulate damage at molecular, cellular, and systems levels, which scale up to become clinically detectable [1, 2]. Although exactly which deficits accumulate in which people vary, in most people, at some age the number of deficits that they have matters more to their survival than exactly which ones they have [3]. This extends even to death from specific causes such as cardiovascular mortality [4, 5]. Such observations run counter to how most risk factors are related to a given disease/condition (i.e. ‘what are the most critical risk factors for X condition’), to complement what is known about the scale of ageing. It also corresponds to the actuarial definition of frailty, as a lifelong ageing factor that results in people of the same age having variable risks of death [6]. In this it corresponds to the clinical approach to frailty based on deficit accumulation: with time, people accumulate deficits at varying rates.

The deficit accumulation approach views frailty as a general state of age-related risk of poor health outcomes; frailty can be graded by the extent to which individuals have accumulated deficits. Those with the greatest deficits at any age have higher risks for adverse outcomes than do their age peers. One of the ways that frailty exerts its effects in late life is to facilitate disease expression. Consider late-life dementia. As reviewed elsewhere, apparently disease-defining neuropathology and biomarkers [7] as well as polygenic risk [8] and neuropsychological test score performance [9] are more likely to be expressed as clinical dementia, the greater the degree of frailty. Indeed, for some people with high frailty scores, the relationship between even neuropathology and dementia is weak: frailty appears to be the chief risk factor [7]. Population studies identify genetics, social determinants,

and environment to all play a role in deficit accumulation over the life course [7].

At the individual level, deficits accumulate, initially through well-known means, such as DNA methylation, telomere shortening, protein misfolding, inflammation, and problems in DNA repair [1, 2]. These small upstream changes become more prominent before causing cellular, tissue, organ, and clinical dysfunction.

Animal models of frailty have been supportive of these upstream changes and support the model’s generalizability. In human studies, the doubling time of clinical health deficits appears to be 12–15 years [10]. In silico models for frailty have been able to replicate and further support the deficit accumulation theory [11]. Together, these should allow for rapid evaluation and the timely targeting of interventions along the spectrum of this process.

Frailty Index

Many frailty measurement tools count accumulated deficits, with the frailty index (FI) introduced in 2001 being representative [12]. With this approach, working from health records, or epidemiological or trials databases, candidate health variables are evaluated for their potential to be health deficits—in short, to be associated with age and to be related to adverse outcomes [13]. For each individual, the number of deficits is counted and then divided by the number of deficits that were considered, offering a number between 0 (no deficits present—i.e. fittest) and 1 (in theory, if all deficits were present). Given, however, that the degree of frailty is tied to the risk of death, in a properly constructed frailty index (see below) the usual maximum value is around 0.7. At that level of frailty/deficit accumulation, almost no one survives [7].

This tool is broadly used in research, clinical practice, and health policy and continues to be easily implemented in the digital health system [7]. Frailty indexes have been successfully created in animal models (mice/dogs/nonhuman pri-

S. D. Searle · K. Rockwood (✉)
Division of Geriatric Medicine, Dalhousie University and Nova Scotia Health, Halifax, NS, Canada
e-mail: Sam.Searle@nshealth.ca; Kenneth.Rockwood@dal.ca

mates) [7, 14], disease-specific states [15–17], and subclinical frailty information (laboratory and biomarker measures) [18]. This deficit accumulation approach has also been used for non-frailty measurements such as social vulnerability [19].

The type of database a frailty index can be created from is broad, though for clinical feasibility, electronic data are likely best. These datasets include cohort studies, randomized controlled trials (primarily post hoc analysis), electronic health records, comprehensive geriatric assessments, and administrative data [20–26].

Frailty indices may differ broadly as to what is included in each index, though often attempts are made to have the same or similar indices in comparative populations. The validity of this tool is determined by how it is created and behaves, as opposed to the exact variables included. Unexpectedly, the number of items may mean more than each specific variable. Nevertheless, it has always been important that each frailty index covers a broad range of health deficits, including functional measures, comorbidities, and signs/symptoms, else the index may not be as informative [27]. Recently updated [28], the steps in making a frailty index from an existing (or new) study/population include:

1. Select all variables measuring a health problem.
2. Exclude variables with more than 5% missing values.
3. Recode all variables as ‘0’ or ‘1’, representing ‘no deficit’ and ‘deficit’.
4. Exclude variables that are too rare (<1%) or common (>80%).
5. Ensure variables are associated with age.
6. Screen the variables for correlation with each other ($r > 0.95$).
7. At least 30 variables should be included in the index.
8. Calculate the index scores by adding all the present deficits and dividing this sum by the number of deficits considered in each case/person.
9. Test the characteristics of the frailty index.

These steps cover most of the usual process. Further points require clarification for select cases. When using a frailty index longitudinally, the same variables should be included in each longitudinal measurement. At each measurement, the variables should satisfy other criteria (i.e. not be too rare or a saturating deficit). Partial deficits can be used (i.e. deficit scoring of ‘0’, ‘0.5’, ‘1’), and U-shaped variables can be coded as expected. Association with ageing requires attention because the steady-state prevalence can stabilize at later ages, likely due to mortality and new deficit development. Step 9 notes to test the characteristics of the index. This includes its correlation with age, a right-skewed distribution, higher mean FI in females, and 99% of the study sample being assigned scores less than 0.7. Laboratory or performance-based frailty indices tend not to be modified by

sex, and some of these properties may not be apparent if using a narrow age range, a small population, or certain clinical samples.

There remain untested considerations, which mostly stem from a limitation to all frailty assessment tools; a single time-point frailty assessment will be less valid if ongoing recovery or health decline occurs at the clinical or subclinical level. Should those who have treated hypertension still be assigned a health deficit of hypertension? How frail is a patient when they are acutely ill? Similarly, the United Kingdom’s primary care frailty index has been criticized for what appear to be immortal time health deficits, which likely should have some period of re-evaluation, after which they could be removed.

Frailty Assessment During Acute Illness

While on a population level the mean degree of frailty increases over time, individual frailty measurements, even in healthy community-dwelling samples, are dynamic and can show stability, decline, or improvement longitudinally. Expected and current frailty levels are least reliably measured when someone is acutely ill. The deficit accumulation theory for frailty reflects that during acute illness, an individual will have accumulated additional health issues (i.e. reflecting that at that time, they are ‘sick’) but is usually expected to have some health deficits removed or mitigated (i.e. by being treated). There are two key points here. Firstly, for any individual whose frailty was measured at a specific time during this illness, it would become outdated as soon as the measurement is completed. Secondly, recall that frailty indices need to be discriminative as per Step 4. Specifically, deficits need not be too rare, and not saturate. This needs to be satisfied at every measurement longitudinally. Hyperglycaemia/hypoglycaemia, hypotension/hypertension, arrhythmia, renal impairment, hypoxia, delirium, and immobility precluding the ability to perform functional tasks, among many others, can all be very common and fluctuate during acute illness hospitalizations. Naturally, in acute pain and pulse steroids, hypertension for a period does not mean that they have hypertension as a comorbidity.

The frailty level of a patient who is acutely sick in the hospital is best *approximated* by their pre-acute illness frailty status. However, the longer an individual requires hospitalization — the longer deficits remain and are therefore accumulated — the more likely they will have a higher degree of frailty when or if they leave the hospital. Initial treatment response, not dissimilar to the concept of autocorrelation in the general study of complex systems, is important in this setting to void further accumulation. Though this is expected within the deficit accumulation theory of frailty, and clinically a near tautology, these dynamics are not extensively studied.

The dynamic measurements of frailty during hospitalization are not well understood, and therefore, further work needs to be done. This will lead to clinically useful tools to help in prognostication, identify populations for intervention, and determine targets to be intervened upon with respect to further frailty development. Though untested, cognitive states (delirium) and functional mobility may be clinically measurable and meaningful markers of dynamic frailty change during acute illness [29, 30]. Frailty indices containing pre-clinical deficits, like the laboratory frailty index, could be dynamically measured in relatively brief time periods, forecasting — in near real time — frailty trajectory during acute illness.

Frailty in Relation to Social Vulnerability

As noted, social vulnerability—sometimes defined as the ‘disadvantage conveyed by poor social conditions’ [31]—can be quantified using a deficit accumulation approach [18]. It is analogous to the concept of frailty, to which it is related. Our group typically considers social vulnerability separately from frailty, and not include it within a frailty index. Instead, we evaluate the contribution of social vulnerability in a multivariable model. Considering the construct separately can be revealing. An illustrative example is found regarding the outcomes of the least frail older adults. Despite universal access to health care there, a Canadian study of outcomes by tercile of social vulnerability in older adults (aged 70+ years) with the lowest frailty scores (i.e. the least frail) was revealing [32]. Amongst the fittest (least frail people), the 5-year mortality rate for those with the least social vulnerability was 10.8%, compared with 32.5% for people living with the highest social vulnerability. This 22% absolute difference in mortality represented a significantly greater risk: the adjusted hazard ratio was 2.5, with the 95% confidence interval spanning 1.5–4.3.

In a causal model (e.g. with a directed acyclic graph) we see social vulnerability making frailty likely in two broad ways. First, if we consider that a deficit arises when damage goes unremoved, then social vulnerability makes damage more likely—in this sense, following the terminology of Ukraintseva and colleagues, it diminishes *robustness*—the ability to withstand a stress [33]. Consider, for example, people who live in a high-crime area. Greater social advantage is expressed in matters such as more frequent police or even private patrols, the deterrent effects of close monitoring (e.g. multiple closed-circuit cameras), the heft to make sure that street lighting is plentiful and well-maintained, and myriad other manoeuvres and social engagements that make injury or other forms of damage less likely. At the same time, should it occur, access to repair (medical care, physical rehabilitation, counselling, visible signs of community support) enhances *resilience*. As is evident, both assets operate at sev-

eral levels, from the individual to the group, the community, and even government [34]. The influences are especially notable in hospital, where greater social vulnerability increases the risk of longer hospital stays and diminishes the chance of people living in their own homes, at all levels of frailty [35]. Similarly, access to home care is greatest for those with the least social vulnerability [36].

This approach appears to be generalizable across cultures, including across the life course [37–41]. The life course effects of social vulnerability are far-reaching. For example, in a Chinese report, childhood food deprivation increased the chance of late-life frailty [42]. This echoes work from the Survey of Health, Aging, and Retirement in Europe where older Europeans had accumulated about 20% more health deficits than did their age peers if they had experienced hunger as a child [43].

Conclusion

The deficit accumulation approach to frailty aims to tie the number of age-related health deficits together as a means of quantifying the degree of frailty. Its proponents argue that there are many ways to be frail, and that degrees of frailty are discernible clinically, with important consequences for prognosis and for care planning. Care plans must not just define risk: they must encourage practices in which risk might be mitigated.

The deficit accumulation approach has proved to be translatable across settings (population-based, clinical, and bench), countries, cultures, and species. In offering quantitative methods that are easy to understand, and that lend themselves to formal quantitative analysis and reasoning, this way of operationalizing frailty can enhance clinical practices and offer up opportunities for translation that embrace complexity. Even after two decades, there is much to be done, especially now that as of 2021, the leading edge of the Baby Boom is turning age 75, where deficit acceleration is most evident. This is a wave that will dominate much of health care for the professional lifetimes of most current practitioners. An organized way to tackle this challenge, and not just muddle through, is what is required now.

References

1. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: an expanding universe. *Cell*. 2023;186:243–78.
2. Goh J, Wong E, Soh J, Maier AB, Kennedy BK. Targeting the molecular & cellular pillars of human aging with exercise. *FEBS J*. 2023;290:649–68.
3. Mitnitski A, Rockwood K. Aging as a process of deficit accumulation: its utility and origin. *Interdiscip Top Gerontol*. 2015;40:85–98.
4. Farooqi MAM, Gerstein H, Yusuf S, Leong DP. Accumulation of deficits as a key risk factor for cardiovascular morbidity and mor-

- tality: a pooled analysis of 154,000 individuals. *J Am Heart Assoc.* 2020;9:e014686.
5. Wallace LM, Theou O, Kirkland SA, et al. Accumulation of non-traditional risk factors for coronary heart disease is associated with incident coronary heart disease hospitalization and death. *PLoS One.* 2014;9(3):e90475.
 6. Vaupel JW, Manton KG, Stallard E. The impact of heterogeneity in individual frailty on the dynamics of mortality. *Demography.* 1979;16:439–54.
 7. Howlett SE, Rutenberg AD, Rockwood K. The degree of frailty as a translational measure of health in aging. *Nat Aging.* 2021;1(8):651–65.
 8. Ward DD, Ranson JM, Wallace LMK, Llewellyn DJ, Rockwood K. Frailty, lifestyle, genetics and dementia risk. *J Neurol Neurosurg Psychiatry.* 2022;93(4):343–50.
 9. Canevelli M, Wallace LMK, Bruno G, et al. Frailty is associated with the clinical expression of neuropsychological deficits in older adults. *Eur J Neurol.* 2023;31(1):e16072. <https://doi.org/10.1111/ene.16072>.
 10. Hoogendijk EO, Rockwood K, Theou O, et al. Tracking changes in frailty throughout later life: results from a 17-year longitudinal study in the Netherlands. *Age Ageing.* 2018;47:727–33.
 11. Farrell S, Stubbings G, Rockwood K, Mitnitski A, Rutenberg A. The potential for complex computational models of aging. *Mech Ageing Dev.* 2021;193:111403.
 12. Mitnitski AB, Mogilner AJ, Rockwood K. Accumulation of deficits as a proxy measure of aging. *ScientificWorldJournal.* 2001;1:323–36.
 13. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. *Lancet.* 2013;381(9868):752–62. Erratum in: *Lancet.* 2013;382(9901):1328.
 14. Kane AE, Howlett SE. Sex differences in frailty: comparisons between humans and preclinical models. *Mech Ageing Dev.* 2021;198:111546.
 15. Rockwood MR, MacDonald E, Sutton E, et al. Frailty index to measure health status in people with systemic sclerosis. *J Rheumatol.* 2014;41:698–705.
 16. Guaraldi G, Brothers TD, Zona S, et al. A frailty index predicts survival and incident multimorbidity independent of markers of HIV disease severity. *AIDS.* 2015;29:1633–41.
 17. Legge A, Kirkland S, Rockwood K, et al. Construction of a frailty index as a novel health measure in systemic lupus erythematosus. *J Rheumatol.* 2020;47:72–81.
 18. Sapp DG, Cormier BM, Rockwood K, Howlett SE, Heinze SS. The frailty index based on laboratory test data as a tool to investigate the impact of frailty on health outcomes: a systematic review and meta-analysis. *Age Ageing.* 2023;52(1):309.
 19. Andrew MK, Mitnitski AB, Rockwood K. Social vulnerability, frailty and mortality in elderly people. *PLoS One.* 2008;3(5):e2232.
 20. Clegg A, Bates C, Young J, et al. Development and validation of an electronic frailty index using routine primary care electronic health record data. *Age Ageing.* 2016;45:353–60. <https://doi.org/10.1093/ageing/afw039>. Erratum in: *Age Ageing.* 2017 Jan 17.
 21. Kim DH, Schneeweiss S, Glynn RJ, et al. Measuring frailty in medicare data: development and validation of a claims-based frailty index. *J Gerontol A Biol Sci Med Sci.* 2018;73:980–7.
 22. Kim DH, Patorno E, Pawar A, et al. Measuring frailty in administrative claims data: comparative performance of four claims-based frailty measures in the U.S. Medicare Data. *J Gerontol A Biol Sci Med Sci.* 2020;75:1120–5.
 23. Wilkinson C, Wu J, Searle SD, et al. Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial. *BMC Med.* 2020;18(1):401.
 24. Hollinghurst J, Housley G, Watkins A, et al. A comparison of two national frailty scoring systems. *Age Ageing.* 2021;50:1208–14. <https://doi.org/10.1093/ageing/afaa252>.
 25. Cooper L, Loewenthal J, Frain LN, et al. From research to bedside: incorporation of a CGA-based frailty index among multiple comanagement services. *J Am Geriatr Soc.* 2022;70(1):90–8.
 26. Wightman H, Quinn TJ, Mair FS, et al. Frailty in randomised controlled trials for dementia or mild cognitive impairment measured via the frailty index: prevalence and prediction of serious adverse events and attrition. *Alzheimers Res Ther.* 2023;15:110.
 27. Searle SD, Mitnitski A, Gahbauer EA, Gill TM, Rockwood K. A standard procedure for creating a frailty index. *BMC Geriatr.* 2008;8:24. <https://doi.org/10.1186/1471-2318-8-24>.
 28. Theou O, Haviva C, Wallace L, Searle SD, Rockwood K. How to construct a frailty index from an existing dataset in 10 steps. *Age Ageing.* 2023 Dec 1;52(12):afad221. <https://doi.org/10.1093/ageing/afad221>.
 29. Hatheway OL, Mitnitski A, Rockwood K. Frailty affects the initial treatment response and time to recovery of mobility in acutely ill older adults admitted to hospital. *Age Ageing.* 2017;46:920–5.
 30. Richardson S, Murray J, Davis D, et al. Delirium and delirium severity predict the trajectory of the hierarchical assessment of balance and mobility in hospitalized older people: findings from the DECIDE study. *J Gerontol A Biol Sci Med Sci.* 2022;77:531–5.
 31. Mah JC, Penwarden JL, Pott H, Theou O, Andrew MK. Social vulnerability indices: a scoping review. *BMC Public Health.* 2023;23(1):1253.
 32. Andrew MK, Mitnitski A, Kirkland SA, Rockwood K. The impact of social vulnerability on the survival of the fittest older adults. *Age Ageing.* 2012;41:161–5.
 33. Ukraintseva S, Yashin AI, Arbeevev KG. Resilience versus robustness in aging. *J Gerontol A Biol Sci Med Sci.* 2016;71:1533–4.
 34. Andrew MK, Keefe JM. Social vulnerability from a social ecology perspective: a cohort study of older adults from the National Population Health Survey of Canada. *BMC Geriatr.* 2014;14:90.
 35. Mah JC, Godin J, Stevens SJ, et al. Social vulnerability and frailty in hospitalized older adults. *Can Geriatr J.* 2023;26(3):390–9.
 36. Mah J, Stevens, S.J., Keefe, J.M. et al. Social factors influencing utilization of home care in community-dwelling older adults: a scoping review. *BMC Geriatr* 21, 145 (2021). <https://doi.org/10.1186/s12877-021-02069-1>.
 37. Li Y, Xue QL, Odden MC, Chen X, Wu C. Linking early life risk factors to frailty in old age: evidence from the China Health and Retirement Longitudinal Study. *Age Ageing.* 2020;49:208–17.
 38. Rogers NT, Blodgett JM, Searle SD, Cooper R, Davis DHJ, Pinto Pereira SM. Early-life socioeconomic position and the accumulation of health-related deficits by midlife in the 1958 British Birth Cohort Study. *Am J Epidemiol.* 2021;190:1550–60.
 39. Abeliansky AL, Erel D, Strulik H. Social vulnerability and aging of elderly people in the United States. *SSM Popul Health.* 2021;16:100924.
 40. Haapanen MJ, Jylhävä J, Kortelainen L, et al. Early-life factors as predictors of age-associated deficit accumulation across 17 years from midlife into old age. *J Gerontol A Biol Sci Med Sci.* 2022;77:2281–7.
 41. Baranyi G, Welstead M, Corley J, et al. Association of life-course neighbourhood deprivation with frailty and frailty progression from ages 70 to 82 years in the Lothian birth cohort 1936. *Am J Epidemiol.* 2022;191:1856–66.
 42. Ye C, Aihemaitijiang S, Wang R, Halimulati M, Zhang Z. Associations between early-life food deprivation and risk of frailty of middle-age and elderly people: evidence from the China Health and Retirement Longitudinal Study. *Nutrients.* 2021;13:3066.
 43. Abeliansky AL, Strulik H. Hungry children age faster. *Econ Hum Biol.* 2018;29:211–20.



Prevalence, Incidence, and Risk Factors of Frailty

3

Gotaro Kojima, Reijiro Aoyama, and Steve Iliffe

Introduction

Frailty is an age-related vulnerable state associated with increased risk of adverse health outcomes [1]. With an acceleration of population aging across the world, many countries will see an increase in the number of frail older adults. Given its significant impacts on healthcare systems and societies, frailty is now considered to be an emerging public health priority [2]. It is therefore vitally important for all stakeholders to better understand the epidemiology, etiology, and pathophysiology of frailty based on available evidence. This chapter focuses on the prevalence, incidence, and risk factors for frailty.

Prevalence of Frailty

Previous frailty research has accumulated epidemiological evidence of frailty [1, 2], and several studies have provided pooled prevalence data. One of the first published systematic reviews and meta-analyses of frailty authored by Collard and colleagues included 21 countries (mostly Western and high-income) and showed that the overall weighted prevalence of frailty is 10.7%, with prevalence recorded by individual studies ranging widely from 4.0% to 59.1% [3]. As part of the ADVANTAGE Joint Action, a European initiative to address frailty in older adults, the researchers used data from European countries and revealed that pooled prevalence of frailty in

community settings was 12% [4]. Another study focused on frailty in low- and middle-income countries and found a higher pooled prevalence of 17.4% than that shown by the two studies above. Unsurprisingly, a similarly high pooled prevalence of 19.6% was provided by another meta-analysis study that examined mostly low- or middle-income countries in Latin America and the Caribbean [5]. Finally, the latest systematic review and meta-analysis study collected a large amount of data from 240 studies from 62 countries and showed that pooled frailty prevalence is around 18% [6].

Some characteristic findings were shared by these studies. Definitions of frailty appear to influence the prevalence of frailty; specifically, the pooled prevalence of frailty from studies using physical frailty was lower than that from studies using multidimensional frailty, such as a deficit accumulation model, for example, 9.9% vs. 13.6% [3], 12% vs. 16% [4], or 12% vs. 24% [6]. According to a study that examined frailty prevalence in the same cohort but using eight different scales, the prevalence of frailty varies considerably from 6.1% using the FRAIL scale to 43.9% with the Groningen Frailty Indicator [7]. Although any frailty tools are able to identify high risk groups, different tools capture different groups of individuals, thus providing different estimates of prevalence of frailty. Advanced age is a strong risk factor of frailty, and pooled estimate of frailty prevalence rises as populations become older [1]. The meta-analysis by Collard showed that the prevalence of frailty is less than 5% among individuals aged 65–69 years while rising to more than 25% among individuals aged 85 or older [3]. Another study further investigated the prevalence of frailty according to the minimum age cut-off at study entry (50–59, 60–69, 70–79, 80–89, and 90+), and showed that frailty becomes more prevalent from 11% up to 51% in a dose-response manner as the minimum age cut-off increases [6]. This study also showed a significant association between the mean age of participants and frailty prevalence by a meta-regression method [6]. Biological female sex is a well-known risk factor of frailty, and a few meta-analysis studies showed higher prevalence of frailty in women than in men (9.6% vs. 5.2%

G. Kojima (✉)

Department of Research, CLINIC 9ru, Tokyo, Japan
e-mail: gotarokojima@yahoo.co.jp

R. Aoyama

Department of Japanese Studies, The Chinese University of Hong Kong, Shatin, Hong Kong
e-mail: reiaoyama@cuhk.edu.hk

S. Iliffe

Research Department of Primary Care and Population Health, University College London, London, UK
e-mail: s.iliffe@ucl.ac.uk

[3], 15% vs. 11% [6]). Given the various factors described above which can pose a significant impact on estimates of frailty prevalence, when assessing prevalence of frailty, it is important to take into consideration the frailty tools used, age distribution, sex proportion of the populations, and other related factors.

Incidence of Frailty

Compared with prevalence, less is known regarding the natural course or development of frailty [8–10]. It is important to understand how people develop frailty during their lifetime in order to deepen our knowledge of this issue and facilitate future research into the pathophysiology of frailty.

One systematic review focusing on the incidence of frailty was published in 2018 [10]. This review was done as part of a European research project on frailty and searched for original articles from both EU and non-EU countries providing incidence of frailty, defined as the number of new cases of frailty per population in a certain time period [10]. Of six included studies, the lowest incidence of frailty was 3.9% from 727 older adults aged 65 or greater in Germany who had been followed up for approximately 3 years. The highest incidence was 13.0% provided by a study including 6,306 Chinese people older than 55 years with a mean age of 70 years tracked over a period of 1 year [11]. The authors considered one study showing the incidence of 51.4% in 74 Aboriginal Australian people older than 45 years over 6.7 years [12] as an extreme outlier.

The other systematic review conducted a more comprehensive series of analyses on the incidence of frailty and prefrailty using data from 46 studies [9]. Among 100,313 nonfrail (robust or prefrail) older adults, 13.6% developed frailty over a median follow-up of 3 years, with the pooled incidence rate of 43.4 cases per 1000 person-years. The pooled incidence rate was significantly higher in prefrail than in robust people, at 62.7 vs. 12.0 cases per 1,000 person-years. This study also examined the development of prefrailty among 32,268 robust individuals, showing an incidence of prefrailty of 30.9% over a median follow-up of 2.5 years and a pooled incidence rate of 150.6 cases per 1,000 person-years. Another interesting finding was a significantly higher incidence and incidence rates of frailty and prefrailty in women than in men: frailty 15.6% vs. 9.2%, 44.8 vs. 24.3 cases per 1,000 person-years; prefrailty 40.1% vs. 32.6%, 173.2 vs. 129.0 cases per 1,000 person-years. The authors also conducted multivariable random-effects meta-regression analyses and found that four factors were associated with the incidence of frailty. First, measuring frailty using the frailty phenotype was associated with higher incidence than using the other tools (adjusted odds ratio = 1.48). Second, although the study location did not have significant

impacts on the incidence of frailty, studies from high-income countries were associated with a significantly lower frailty incidence compared with studies from low- and middle-income countries (adjusted odds ratio = 0.563). Third, the male-only cohort studies were associated with significantly lower incidence of frailty than mixed cohort studies (adjusted odds ratio = 0.55). Fourth, more recent studies were significantly associated with lower incidence of frailty than earlier studies (adjusted odds ratios = 0.24 and 0.42 for studies published in 2010–2014 and 2015–2019, respectively, compared with studies published in 2009 or earlier).

Risk Factors of Frailty

Many studies have investigated risk factors for frailty [1], and their findings were collected and summarized by several systematic reviews [13–17]. Sociodemographic factors, such as age, sex, education, marital status, and living situation, have been frequently examined. Advanced age is almost always a risk factor of frailty, and a 1-year increase in age is associated with 5% higher frailty risk (pooled odds ratio = 1.05, 95% = 1.03–1.08, $p < 0.001$) [16]. It is well documented that women live longer than men, but paradoxically are likely to have higher prevalence and severity of frailty [18]. This sex difference is observed in different age groups and populations [19], and has been confirmed by meta-analyses [13, 14]. It seems that biological factors, in addition to social and behavioral ones, play some role in producing the sex difference, as earlier age at menopause [20, 21] and higher number of pregnancies [22] are associated with significantly higher risk of frailty. A U-shaped association was observed between body weight and frailty, and those who are underweight and overweight are at an increased risk of frailty. As compared with a normal BMI as the reference group, pooled relative risks of frailty are 1.45 (95%CI = 1.10–1.90, $p < 0.01$) for the underweight group (BMI < 18.5 kg/m²), 0.93 (95%CI = 0.85–1.02, $p = 0.11$) for the overweight group (BMI = 25.1–30 kg/m²), and 1.40 (95%CI = 1.17–1.67, $p < 0.01$) for the obese group (BMI > 30 kg/m²) [23]. Poor education factors, such as fewer years of education or not having mandatory education, are associated with frailty risk [14]. Although educational level is mostly fixed during the period of young adulthood and remains stable afterwards, it can affect health through various related factors. For example, education can lead to more accurate health knowledge, and thus better lifestyle, including regular exercise and healthier diet, and to a better job and higher income, which will in turn enable access to healthier foods and better living environments. One longitudinal study explored explanatory factors mediating the associations between low educational levels and frailty and found that the strongest explanatory effect was income, followed by behavioral fac-

tors (smoking, alcohol use, obesity), mental factors (depressive symptoms, cognitive function, mastery, self-efficacy), and biomedical factors (number of chronic diseases, CRP, vitamin D level, IGF-1 level), and, interestingly, that social factors (having a partner, network size, emotional support) contributed little [24]. Low income itself has been shown to be associated with higher risk of frailty [25]. Multiple studies have examined living environments, such as neighborhood characteristics, marital status, and living situation, in association with frailty risk, and showed that living in a deprived neighborhood [26], not being married [27], and living alone [28] are associated with higher risk of frailty. A noticeable racial/ethnic disparity in frailty has been identified by previous research. For example, US studies have consistently shown that black race is associated with a higher risk of frailty, which could be attributable to low socioeconomic status, poor health status, or genetic polymorphisms [25]. Furthermore, several US studies stratified frailty risks according to race/ethnicity and found that racial and ethnic minority groups, particularly blacks and Hispanics, had excessively higher prevalence of frailty compared to non-Hispanic whites [29–31]. The underlying mechanisms for the disparity seem multifactorial [30]. Some studies attempted to explore the underlying causes further and demonstrated interesting findings. In one study, only socioeconomic status-related factors remained significant while race did not when mutually adjusted, suggesting the socioeconomic status may account for the racial disparity in frailty [32]. Another study showed that the higher frailty risk seen in Mexican Americans when compared with European Americans disappeared when ethnic-specific frailty criteria were used, which suggests that the frailty disparity may be largely due to the use of the frailty measurement tool, not underlying frailty per se [33].

Lifestyle and behavioral factors have also been well studied. Examples are diet, smoking, alcohol use, or exercise [25]. Poor diet and malnutrition are prevalent in older adults and are associated with frailty [34]. The Mediterranean diet is a well-known dietary pattern with health benefits [35] and is shown to be inversely associated with frailty [36]. Among different micro- and macro-nutrients that have been examined, protein is considered to be the most relevant and important factor for frailty, given that sarcopenia, age-related loss of muscle mass and functions, is the core feature of frailty [37, 38]. Multiple studies have shown that lower protein or amino acids are associated with higher risk of frailty and its related factors [34, 38]. Smoking and low level of exercise are shown to be associated with frailty [39, 40], while the association between alcohol use and frailty seems more complicated [41, 42]. Physical inactivity is recognized as one of the contributing risk factors for frailty [40], and physical activity/exercise is currently considered to be the most effective intervention against frailty [43].

Summary

This chapter focuses on the prevalence, incidence, and risk factors of frailty by referring to up-to-date systematic reviews and their meta-analyses. Understanding the prevalence, incidence, and risk factors of frailty will help us identify and stratify the risks of frailty, predict its development or progression, and provide appropriate interventions to reverse the severity of frailty or proactively prevent its related adverse outcomes. It will also contribute to more comprehensive health management of older adults.

References

1. Clegg A, Young J, Iliffe S, et al. Frailty in elderly people. *Lancet*. 2013;381(9868):752–62.
2. Kojima G, Liljas AEM, Iliffe S. Frailty syndrome: implications and challenges for health care policy. *Risk Manag Healthc Policy*. 2019;12:23–30.
3. Collard RM, Boter H, Schoevers RA, et al. Prevalence of frailty in community-dwelling older persons: a systematic review. *J Am Geriatr Soc*. 2012;60(8):1487–92.
4. O’Caoimh R, Galluzzo L, Rodríguez-Laso Á, et al. Prevalence of frailty at population level in European Advantage Joint Action Member States: a systematic review and meta-analysis. *Ann Ist Super Sanita*. 2018;54(3):226–38.
5. Da Mata FA, Pereira PP, Andrade KR, et al. Prevalence of frailty in Latin America and the Caribbean: a systematic review and meta-analysis. *PLoS One*. 2016;11(8):e0160019.
6. O’Caoimh R, Sezgin D, O’Donovan MR, et al. Prevalence of frailty in 62 countries across the world: a systematic review and meta-analysis of population-level studies. *Age Ageing*. 2021;50(1):96–104.
7. Theou O, Brothers TD, Mitnitski A, et al. Operationalization of frailty using eight commonly used scales and comparison of their ability to predict all-cause mortality. *J Am Geriatr Soc*. 2013;61(9):1537–51.
8. Kojima G, Taniguchi Y, Iliffe S, et al. Transitions between frailty states among community-dwelling older people: a systematic review and meta-analysis. *Ageing Res Rev*. 2019;50:81–8.
9. Ofori-Asenso R, Chin KL, Mazidi M, et al. Global incidence of frailty and prefrailty among community-dwelling older adults: a systematic review and meta-analysis. *JAMA Netw Open*. 2019;2(8):e198398.
10. Galluzzo L, O’Caoimh R, Rodríguez-Laso Á, et al. Incidence of frailty: a systematic review of scientific literature from a public health perspective. *Ann Ist Super Sanita*. 2018;54(3):239–45.
11. Zheng Z, Guan S, Ding H, et al. Prevalence and incidence of frailty in community-dwelling older people: Beijing Longitudinal Study of Aging II. *J Am Geriatr Soc*. 2016;64(6):1281–6.
12. Hyde Z, Flicker L, Smith K, et al. Prevalence and incidence of frailty in Aboriginal Australians, and associations with mortality and disability. *Maturitas*. 2016;87:89–94.
13. Qin Y, Hao X, Lv M, et al. A global perspective on risk factors for frailty in community-dwelling older adults: a systematic review and meta-analysis. *Arch Gerontol Geriatr*. 2023;105:104844.
14. Wang X, Hu J, Wu D. Risk factors for frailty in older adults. *Medicine*. 2022;101(34):e30169.
15. Shakya S, Bajracharya R, Ledbetter L, et al. The association between cardiometabolic risk factors and frailty in older adults: a systematic review. *Innov Aging*. 2022;6(5):32.

16. Xu R, Li Q, Guo F, et al. Prevalence and risk factors of frailty among people in rural areas: a systematic review and meta-analysis. *BMJ Open*. 2021;11(4):e043494.
17. Feng Z, Lugtenberg M, Franse C, et al. Risk factors and protective factors associated with incident or increase of frailty among community-dwelling older adults: a systematic review of longitudinal studies. *PLoS One*. 2017;12(6):e0178383.
18. Gordon EH, Peel NM, Samanta M, et al. Sex differences in frailty: a systematic review and meta-analysis. *Exp Gerontol*. 2017;89:30–40.
19. Gordon EH, Hubbard RE. The pathophysiology of frailty: why sex is so important. *J Am Med Dir Assoc*. 2018;19(1):4–5.
20. Kojima G, Taniguchi Y, Ogawa K, et al. Age at menopause is negatively associated with frailty: a systematic review and meta-analysis. *Maturitas*. 2022;165:94–9.
21. Kojima G, Taniguchi Y, Aoyama R, et al. Earlier menopause is associated with higher risk of incident frailty in community-dwelling older women in England. *J Am Geriatr Soc*. 2022;70(9):2602–9.
22. Kojima G, Ogawa K, Iliffe S, et al. Number of pregnancies and trajectory of frailty index: English longitudinal study of ageing. *J Am Med Dir Assoc*. 2020;21(9):1249–53.
23. Yuan L, Chang M, Wang J. Abdominal obesity, body mass index and the risk of frailty in community-dwelling older adults: a systematic review and meta-analysis. *Age Ageing*. 2021;50(4):1118–28.
24. Hoogendijk EO, van Hout HP, Heymans MW, et al. Explaining the association between educational level and frailty in older adults: results from a 13-year longitudinal study in the Netherlands. *Ann Epidemiol*. 2014;24(7):538–44.
25. Mello Ade C, Engstrom EM, Alves LC. Health-related and socio-demographic factors associated with frailty in the elderly: a systematic literature review. *Cad Saude Publica*. 2014;30(6):1143–68.
26. Fritz H, Cutchin MP, Gharib J, et al. Neighborhood characteristics and frailty: a scoping review. *Gerontologist*. 2020;60(4):e270–85.
27. Kojima G, Walters K, Iliffe S, et al. Marital status and risk of physical frailty: a systematic review and meta-analysis. *J Am Med Dir Assoc*. 2020;21(3):322–30.
28. Kojima G, Taniguchi Y, Kitamura A, et al. Is living alone a risk factor of frailty? A systematic review and meta-analysis. *Ageing Res Rev*. 2020;59:101048.
29. Bandeen-Roche K, Seplaki CL, Huang J, et al. Frailty in older adults: a nationally representative profile in the United States. *J Gerontol A Biol Sci Med Sci*. 2015;70(11):1427–34.
30. Usher T, Buta B, Thorpe RJ, et al. Dissecting the racial/ethnic disparity in frailty in a nationally representative cohort study with respect to health, income, and measurement. *J Gerontol A Biol Sci Med Sci*. 2021;76(1):69–76.
31. Hirsch C, Anderson ML, Newman A, et al. The association of race with frailty: the cardiovascular health study. *Ann Epidemiol*. 2006;16(7):545–53.
32. Szanton SL, Seplaki CL, Thorpe RJ Jr, et al. Socioeconomic status is associated with frailty: the Women's Health and Aging Studies. *J Epidemiol Community Health*. 2010;64(1):63–7.
33. Espinoza SE, Hazuda HP. Frailty in older Mexican-American and European-American adults: is there an ethnic disparity? *J Am Geriatr Soc*. 2008;56(9):1744–9.
34. Artaza-Artabe I, Sáez-López P, Sánchez-Hernández N, et al. The relationship between nutrition and frailty: effects of protein intake, nutritional supplementation, vitamin D and exercise on muscle metabolism in the elderly. A systematic review. *Maturitas*. 2016;93:89–99.
35. Kojima G, Avgerinou C, Iliffe S, et al. Adherence to Mediterranean diet reduces incident frailty risk: systematic review and meta-analysis. *J Am Geriatr Soc*. 2018;66(4):783–8.
36. Poursalehi D, Lotfi K, Saneei P. Adherence to the Mediterranean diet and risk of frailty and pre-frailty in elderly adults: a systematic review and dose-response meta-analysis with GRADE assessment. *Ageing Res Rev*. 2023;87:101903.
37. Coelho-Junior HJ, Marzetti E, Picca A, et al. Protein intake and frailty: a matter of quantity, quality, and timing. *Nutrients*. 2020;12(10):2915.
38. Coelho-Junior HJ, Calvani R, Picca A, et al. Protein intake and frailty in older adults: a systematic review and meta-analysis of observational studies. *Nutrients*. 2022;14(13):2767.
39. Amiri S, Behnezhad S. Systematic review and meta-analysis of the association between smoking and the incidence of frailty. *Neuropsychiatrie*. 2019;33(4):198–206.
40. Marzetti E, Calvani R, Tosato M, et al. Physical activity and exercise as countermeasures to physical frailty and sarcopenia. *Aging Clin Exp Res*. 2017;29(1):35–42.
41. Kojima G, Liljas A, Iliffe S, et al. A systematic review and meta-analysis of prospective associations between alcohol consumption and incident frailty. *Age Ageing*. 2018;47(1):26–34.
42. Strandberg AY, Trygg T, Pitkälä KH, et al. Alcohol consumption in midlife and old age and risk of frailty: alcohol paradox in a 30-year follow-up study. *Age Ageing*. 2018;47(2):248–54.
43. Negm AM, Kennedy CC, Thabane L, et al. Management of frailty: a systematic review and network meta-analysis of randomized controlled trials. *J Am Med Dir Assoc*. 2019;20(10):1190–8.



Integration: A Unified Frailty Framework

4

Domenico Azzolino and Matteo Cesari

Integration: A Unified Frailty Framework

Older people are burdened by the coexistence of multiple, often chronic conditions. In this context, psychological, socio-economic, and cultural issues may play a role by increasing the vulnerability of older persons to endogenous and exogenous stressors. Unfortunately, traditional models of care, largely built and focused on a disease-centered approach, are woefully unprepared to address the high biological, clinical, and social complexity of older people, especially the most vulnerable ones [1].

The development of the frailty concept has historically represented an opportunity to pay attention to neglected aspects of the older person's health with the aim of personalize care interventions. It has the potential for reshaping our obsolete care systems, driving them towards models that are more respectful of the individual's priorities, needs, and values. Indeed, frailty induces clinicians to look beyond the traditional nosological entities promoting a multidisciplinary and integrated approach focused on the older person's functions and capacities.

During the past couple of decades, the number of publications on frailty markedly increased, mainly because of the first attempts to operationalize this condition. Interestingly, an editorial published in 1968 in the *British Medical Journal* [2] explained the difference between "Old and Frail," stressing the inadequacy of the current models of care for addressing the evolving needs of the aging population. For many years, frailty has never been formally defined but used as a vague concept to generally indicate persons expressing a particularly high risk of adverse events due to their multiple clinical and disabling conditions.

D. Azzolino (✉)
Geriatric Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore
Policlinico, Milan, Italy

M. Cesari
Department of Clinical Sciences and Community Health,
University of Milan, Milan, Italy
e-mail: mcesari@who.int

Starting at the beginning of this century, several groups of researchers and clinicians started to propose operational definitions of frailty, in the attempt to raise awareness about this critical condition and improve care for older persons. Such increasing interest was indeed very prolific. Just recently, Buta et al. [3] reported a total of 67 frailty instruments available in the literature, of which nine instruments were "highly cited" (i.e., with 200 or more citations), and these figures might be significantly higher today. In other words, the same concept (i.e., frailty) is measured using many different instruments. Unfortunately, although all these instruments were formally validated in the literature (mainly as predictive of adverse health-related outcomes), their agreement tends to be quite modest. In other words, each of these instruments seems to capture a different model of frailty [4, 5].

Of course, having so many (potentially conflicting) instruments to measure the same concept has frequently been the cause of debates, misleading messages, and different viewpoints in the field. The existence of several tools to measure frailty frequently resulted in a lack of agreement slowing the broad implementation of these instruments in the clinical practice [6]. The objective to provide adapted care to older persons for which frailty was there had become apparently (and paradoxically) secondary to the instruments used to measure it [1].

To standardize the emerging literature and practices, a panel of international experts in the field met in Orlando (FL, USA) in 2013 [7]. The resulting consensus paper provided an agreed theoretical definition of frailty, describing it as "a clinical state in which there is an increase in an individual's vulnerability for developing increased dependency and/or mortality when exposed to a stressor." It was clarified that frailty can result from a variety of illnesses and medical conditions and the need to adopt a multidimensional approach to manage it. Frailty was clearly differentiated from the concept of multimorbidity (i.e., the presence of two or more concomitant diseases), being diseases only a part, often marginal, of the frailty problem. The group did not endorse a specific instrument for measuring frailty and remained focused at standardizing its "higher level" theoretical concept.

As soon as the theory of the concept is established, it makes more sense that frailty might then be perceived by different models (focusing on one or more specific aspects of the condition) and instruments (translating into numbers the clinical observation from the model) [8]. To date, as discussed in other chapters of the present book, the most commonly adopted models of frailty are the phenotypic model proposed by Fried and colleagues [9], the health deficit accumulation model developed by Rockwood and Mitniski [10], and the Tilburg Frailty Indicator proposed by Gobbens et al. [11]. The number of instruments is huge and exponentially increasing, considering that one single model may be translated and adapted in multiple ways (with different results) [12].

Despite frailty having its origins in geriatrics, it is today discussed and adopted by many specialties struggling to find solutions to the increasing complexity of their aging populations (i.e., neurology [13], orthopedics [14], cardiology [15], infectious disease medicine [16], and oncology [17]). Frailty is used in the evaluation of persons living with HIV [18] or Down's syndrome [19]. It is growingly measured in older persons with end-stage conditions (i.e., liver [20] or renal [21] diseases) to better allocate care interventions and identify needs for alternative approaches (e.g., palliation). Frailty is indeed increasingly used to measure “biological age” and overcome the paradigm of chronological age.

Interestingly, the multidimensional nature of frailty replacing the paradigm of chronological age may determine a different way of conducting research in older persons. It means relying on biology rather than on years of life in the estimate of the individual's complexity. The approach may allow to overcome some of the issues of current research that is still too rigidly focused on unidimensional variables and misses the heterogeneous complexity of the older person, resulting in a poor representativeness of the real life [22].

As soon as frailty is considered a biological measure of aging, it also becomes of special interest also for preclinical research. After all, different frailty models have demonstrated to possess a strong biological background and mirror the dynamic phenomenon of aging (Fig. 4.1). For example, the Frailty Index has shown to exponentially increase with aging up to a critical threshold of incompatibility between health deficit accumulation and life [23]. This behavior of the model has consistently been documented across species (e.g., *Caenorhabditis elegans* [24], mice [25], dogs [26]), becoming an interesting asset for promoting translational research on aging. Similarly, the phenotypic model of frailty has also shown important (and consistent) biological patterns again linking the frailty condition to aging [27]. In other words, working on frailty may mean acting on aging, capturing the heterogeneous clinical manifestations caused by the biological exhaustion of the systems.

As soon as frailty represents the dynamic process of aging, its detection might become the entry door to approach




Fig. 4.1 Time-related modification of the Frailty Index from the baseline assessment (red histograms) to the 18-month follow-up visit (blue histograms) of the Yale Precipitating Events Project participants. The figure demonstrates the evolution of frailty over time (i.e., increase of health deficit accumulation) and the biological background of the model (i.e., incompatibility between excess accumulation of deficits and life beyond a certain [i.e., about 0.7] threshold). The figure is reproduced from Searle et al. [23] under the terms of the Creative Commons Attribution License

the age-related biology responsible for many clinical conditions of the older person. Given its multidimensional nature, the assessment and management of frailty requires a multidimensional approach [6, 28–30]. It cannot be based on the unidimensional model characterizing the traditional stand-alone disease approach because the underlying pathophysiological mechanism is not any more straightforward and organ-centered. It is necessary to be comprehensive and consider the wide spectrum of nosological and non-nosological features of frailty. The evaluation must consider the environment where the person lives because it plays a critical role in the design and implementation of the care plan.

To date, no pharmacological agent has been identified against frailty. Although several molecules are under investigation [31], the solution of a “magic pill” is likely far from being achieved. Some hope it might reside in geroscience and the research on the so-called “hallmarks of aging” [32]. The exploration of the aging process and the biological determinants of chronic conditions may help identify potential new targets of interventions and modify the inner mechanisms at the basis of the development of diseases.

However, strategies to prevent or improve frailty currently (and pragmatically) reside in the multidisciplinary and multidimensional approach depicted by the comprehensive geriatric assessment (CGA). The CGA is defined as “A multidimensional, multidisciplinary diagnostic and therapeutic process conducted to determine the medical, mental, and functional problems of older people with frailty” [33]. It

represents the gold standard intervention of geriatric medicine, which finds in its target population all those persons presenting the biological, clinical, and social expressions of increased vulnerability (i.e., frailty). The objective of the CGA is the development of a coordinated and integrated intervention plan (including diagnosis, treatment, and follow-up) to maximize the health status of the individual [33, 34]. Frailty can then be perceived as the cross-road in the clinical setting distinguishing persons who may have access to standard care (because biologically fit) from those who might better benefit from adapted geriatric interventions (because biologically aged or frail) [1].

Notwithstanding, it is widely agreed that frailty screening should be a necessary component of the clinical routine, especially in the community and primary care settings (in order to promote a preventive approach in the care provision) [35, 36]. Interestingly, the British Geriatrics Society proposed to screen for frailty at the primary care level without recommending a unique instrument but proposing a set of possible ones [37]. The document *Fit for Frailty* instead gave more relevance to the intervention to put in place after the detection of frailty, that is the CGA. In other words, (1) it is important to screen frailty, (2) it is marginally important how we do it (as soon as the instrument is validated and fits for the purpose), and (3) the CGA (the gold standard intervention) is the critical component of the process. After all, besides the fact that the systematic screening of frailty might not be cost-effective, it is important to consider that the detection and measurement of frailty make sense only if followed by an evidence-based intervention. Detecting frailty without a consequent, validated action may simply lead to overdiagnosis, malpractice, and ethical issues.

Last but not least, it is important to mention in this chapter how the frailty model has been inspiring the work conducted on healthy aging by the World Health Organization (WHO) over the past years [38]. The novel framework based on the interaction between intrinsic capacity (i.e., the composite of the physical and mental capacities) and environment in the definition of the older person's functional ability is aligned with the comprehensive approach traditionally followed by geriatricians in the management of frail individuals. Under the new framework, the WHO is recommending the re-orientation of services and policies for making them more responsive to the older person's needs, values, and priorities. The activities are based on the multidimensional assessment of the individual by a multidisciplinary team within an integrated care model for the development and implementation of a person-centered intervention. Indeed, the wording and the dynamics are strongly rooted in the frailty background cultivated over the years by geriatricians [39].

In conclusion, the condition of frailty can be used for leveraging the reshaping of the health and social care systems towards a person-centered, multidisciplinary, and integrated approach. In this context, it is important to consider frailty as

a high-level concept, without confusing its meaning with the specific models or instruments used to measure it in the clinical and research practice.

References

1. Cesari M, Marzetti E, Thiem U, Pérez-Zepeda MU, Abellan Van Kan G, Landi F, et al. The geriatric management of frailty as paradigm of “The end of the disease era”. *Eur J Intern Med.* 2016;31:11–4.
2. Author. Old and frail. *Br Med J.* 1968;1(5594):723–4.
3. Buta BJ, Walston JD, Godino JG, Park M, Kalyani RR, Xue QL, et al. Frailty assessment instruments: Systematic characterization of the uses and contexts of highly-cited instruments. *Ageing Res Rev.* 2016;26:53–61.
4. Oviedo-Briones M, Laso ÁR, Carnicero JA, Cesari M, Grodzicki T, Gryglewska B, et al. A comparison of frailty assessment instruments in different clinical and social care settings: the frailtools project. *J Am Med Dir Assoc.* 2021;22(3):607.e7–607.e12.
5. Aguayo GA, Donneau AF, Vaillant MT, Schritz A, Franco OH, Stranges S, et al. Agreement between 35 published frailty scores in the general population. *Am J Epidemiol.* 2017;186(4):420–34.
6. Walston J, Buta B, Xue QL. Frailty screening and interventions: considerations for clinical practice. *Clin Geriatr Med.* 2018;34(1):25–38.
7. Morley J, Vellas B, Abellan van Kan G, Anker S, Bauer J, Bernabei R, et al. Frailty consensus: a call to action. *J Am Med Dir Assoc.* 2013;14(6):392–7.
8. Cesari M, Canevelli M, Calvani R, Aprahamian I, Inzitari M, Marzetti E. Editorial: The management of frailty: barking up the wrong tree. *J Frailty Aging.* 2022;11(2):127–8.
9. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. *J Gerontol A Biol Sci Med Sci.* 2001;56(3):146–56.
10. Mitnitski AB, Mogilner AJ, Rockwood K. Accumulation of deficits as a proxy measure of aging. *ScientificWorldJournal.* 2001;1:323–36.
11. Gobbens RJ, Boersma P, Uchmanowicz I, Santiago LM. The Tilburg frailty indicator (TFI): new evidence for its validity. *Clin Interv Aging.* 2020;15:265–74.
12. Theou O, Cann L, Blodgett J, Wallace LMK, Brothers TD, Rockwood K. Modifications to the frailty phenotype criteria: systematic review of the current literature and investigation of 262 frailty phenotypes in the Survey of Health, Ageing, and Retirement in Europe. *Ageing Res Rev.* 2015;21:78–94.
13. Canevelli M, Cesari M, Remiddi F, Trebbastoni A, Quarata F, Vico C, et al. Promoting the assessment of frailty in the clinical approach to cognitive disorders. *Front Aging Neurosci.* 2017;9:36. <https://doi.org/10.3389/fnagi.2017.00036>.
14. Krishnan M, Beck S, Havelock W, Eeles E, Hubbard R, Johansen A. Predicting outcome after hip fracture: using a frailty index to integrate comprehensive geriatric assessment results. *Age Ageing.* 2014;43(1):122–6.
15. Lilamand M, Dumonteil N, Nourhashemi F, Hanon O, Marcheix B, Toulza O, et al. Gait speed and comprehensive geriatric assessment: two keys to improve the management of older persons with aortic stenosis. *Int J Cardiol.* 2014;173(3):580–2.
16. Guaraldi G, Rockwood K. Geriatric-HIV medicine is born. *Clin Infect Dis.* 2017;65(3):507–9.
17. Cohen H, Smith D, Sun C, Tew W, Mohile S, Owusu C, et al. Frailty as determined by a comprehensive geriatric assessment-derived deficit-accumulation index in older patients with cancer who receive chemotherapy. *Cancer.* 2016;122(24):3865–72.
18. Guaraldi G, Brothers T, Zona S, Stentarelli C, Carli F, Malagoli A, et al. A frailty index predicts survival and incident multimor-